Ian Mortimer

PRESIDENT, CEO & INTERIM CFO

Ian Mortimer (PRESIDENT, CEO & INTERIM CFO) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Xenon Pharmaceuticals Inc. (XENE). The largest single filing was $17.0M of XENE (281,269 sh across 10 lots, as filed), executed Mar 9.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$21.1M

shares × price, as filed

Last traded

Mar 13

Filed Mar 13

Median ADV $85.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $23.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

XENE

Xenon Pharmaceuticals Inc. XENE · 0 buys · 6 sells 6 filings

Recent filings

XENESALE Xenon Pharmaceuticals Inc. View filing → $404K
7,308 sh × $55.23
Exec Mar 13
Filed Mar 13 · 5:30 PM ET XENESALE Xenon Pharmaceuticals Inc. View filing → $17.0M
281,269 sh across 10 lots
Exec Mar 9
Filed Mar 11 · 5:30 PM ET XENESALE Xenon Pharmaceuticals Inc. View filing → $1.7M
37,938 sh × $44.40
Exec Jan 2
Filed Jan 2 · 5:30 PM ET XENESALE Xenon Pharmaceuticals Inc. View filing → $1.0M
23,195 sh across 2 lots
Exec Dec 5 2025
Filed Dec 9 2025 · 5:30 PM ET XENESALE Xenon Pharmaceuticals Inc. View filing → $1.0M
25,000 sh × $40.16
Exec Oct 1 2025
Filed Oct 1 2025 · 5:30 PM ET XENESALE Xenon Pharmaceuticals Inc. View filing → $2.2M
53,851 sh across 3 lots
Exec Jan 23 2025
Filed Jan 27 2025 · 5:30 PM ET